Dec 14 (Reuters) - Redhill Biopharma Ltd RDHL.TA -
* Redhill, Intelgenx expect to re-submit Rizaport U.S. New drug application to FDA in H1 2017, subsequently receive a new PDUFA date
* Redhill Biopharma and Intelgenx announce definitive agreement for commercialization of Rizaport for migraines with Pharmatronic co. in south korea Source text for Eikon: ID:nGNXNNMPMa Further company coverage: RDHL.TA